Putin, Erdogan to meet in Ankara on September 28 — KremlinRussian Politics & Diplomacy September 25, 15:51
Kremlin mum on German right’s success, points out Russian right political lightweightsRussian Politics & Diplomacy September 25, 15:23
Putin, Rouhani discuss Iran's nuclear programRussian Politics & Diplomacy September 25, 14:37
Moscow spices up the city with its spectacular 'Circle of Light' festivalSociety & Culture September 25, 14:34
Russia may help UAE create its own astronaut teamScience & Space September 25, 14:30
Moscow needs to take certain steps for lifting sanctions — leader of Germany’s FDPWorld September 25, 14:23
Historical society vows no new images for slip-up on Kalashnikov monumentSociety & Culture September 25, 14:10
OPEC+ states discuss extending oil cut deal for 3-6 months — sourceBusiness & Economy September 25, 13:49
Press review: How Kurds vote will change Middle East and lawmakers get tough on bankersPress Review September 25, 13:00
MOSCOW, August 19. /TASS/. Russia’s N.F. Gamalei Epidemiology and Microbiology Research Institute has launched clinical trials of anti-Ebola vaccines that will necessitate 4.8 million rubles (about $75,000), the official portal for government procurement said on Friday.
Pre-emptive vaccines against Ebola - Gum Evak and Gum Evak Combi are ready for human trials, the portal said. The main aim of the research is to assess post-vaccination immunity in patients at different points of time after inoculation. Under the forecasts, the research is to end by December 2017.
It was also said that the Gamalei institute had insured volunteers in clinical trials of the registered vaccines. Two million rubles ($31,282) would be paid if a volunteer died. Should a volunteer’s health be damaged leading to a first degree disability, the patient would receive 1.5 million rubles ($26,461), while a second-degree disability would enable him to be awarded one million rubles. However, in cases of third degree disability, the patient would receive 500,000 rubles.
The World Health Organization presented Russia’s pre-emptive vaccines against Ebola - Gum Evak and Gum Avak Combi - in Geneva on February 15. Russia launched work on vaccines in October 2014, and within 15 months, two vaccines were introduced showing maximum efficiency, full safety and high tolerability.
At the moment, the Russian vaccine is the only one that has been registered.
According to the World Health Organization (WHO), more than 11,300 people have died from Ebola in West Africa, primarily in Guinea, Sierra Leone and Liberia. More than 28,600 were infected.